Direct Healthcare Professional Communication (DHPC) on fentanyl-containing transdermal patches: late inclusion of a warning on accidental use
2023.09.01
Active substance: fentanyl
The marketing authorization holders of fentanyl-containing transdermal patches inform in coordination with the Federal Institute for Drugs and Medical Devices (BfArM) that due to existing product lead times, production times and logistical bottlenecks, the implementation of the inclusion of the following warning on the outer packaging and the patch sachet of fentanyl-containing transdermal patches is proceeding in stages:
"Accidental use or ingestion may be fatal"
As a result, packages of fentanyl-containing patches from the companies listed in the DHPC may be in circulation in the next few months, both with the old status and already with the new notices.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN